| Megan Flath, FNP | |
|
222 N 7th St, Bismarck, ND 58501-4436 | |
| (701) 323-6000 | |
| Not Available |
| Full Name | Megan Flath |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 5 Years |
| Location | 222 N 7th St, Bismarck, North Dakota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245877299 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | R37942 (North Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sanford Medical Center Bismarck | Bismarck, ND | Hospital |
| Mckenzie County Healthcare Systems Inc | Watford city, ND | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sanford Bismarck | 9739098575 | 448 |
News Archive
DBV Technologies, an emerging biotechnology company, announced today that it has secured $25.5 million (€19,4 million) in a Series C financing round. The round was co-led by new investors InnoBio Fund (managed by CDC Entreprises within FSI France Investment program) and Lundbeckfond Ventures.
Plexxikon Inc. announces that enrollment has been initiated and the first patient has been treated in the first of two pivotal trials of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly selective drug that targets the BRAFV600E cancer-causing mutation occurring in about 50 percent of melanomas and about eight percent of all solid tumors.
A diet created, studied and reported on by researchers at Rush University Medical Center has been ranked the easiest diet to follow and the second best overall diet (tying in both categories) for 2016 by U.S. News & World Report.
Researchers from Boston University's Slone Epidemiology Center (SEC), in collaboration with Harvard School of Public Health, have found numerous prescription and over-the-counter drugs and supplements use certain chemicals called phthalates as inactive ingredients in their products.
› Verified 9 days ago
| Entity Name | Sanford Bismarck |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811941172 PECOS PAC ID: 9739098575 Enrollment ID: O20031105000403 |
News Archive
DBV Technologies, an emerging biotechnology company, announced today that it has secured $25.5 million (€19,4 million) in a Series C financing round. The round was co-led by new investors InnoBio Fund (managed by CDC Entreprises within FSI France Investment program) and Lundbeckfond Ventures.
Plexxikon Inc. announces that enrollment has been initiated and the first patient has been treated in the first of two pivotal trials of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly selective drug that targets the BRAFV600E cancer-causing mutation occurring in about 50 percent of melanomas and about eight percent of all solid tumors.
A diet created, studied and reported on by researchers at Rush University Medical Center has been ranked the easiest diet to follow and the second best overall diet (tying in both categories) for 2016 by U.S. News & World Report.
Researchers from Boston University's Slone Epidemiology Center (SEC), in collaboration with Harvard School of Public Health, have found numerous prescription and over-the-counter drugs and supplements use certain chemicals called phthalates as inactive ingredients in their products.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Megan Flath, FNP 222 N 7th St, Bismarck, ND 58501-4436 Ph: (701) 323-6000 | Megan Flath, FNP 222 N 7th St, Bismarck, ND 58501-4436 Ph: (701) 323-6000 |
News Archive
DBV Technologies, an emerging biotechnology company, announced today that it has secured $25.5 million (€19,4 million) in a Series C financing round. The round was co-led by new investors InnoBio Fund (managed by CDC Entreprises within FSI France Investment program) and Lundbeckfond Ventures.
Plexxikon Inc. announces that enrollment has been initiated and the first patient has been treated in the first of two pivotal trials of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly selective drug that targets the BRAFV600E cancer-causing mutation occurring in about 50 percent of melanomas and about eight percent of all solid tumors.
A diet created, studied and reported on by researchers at Rush University Medical Center has been ranked the easiest diet to follow and the second best overall diet (tying in both categories) for 2016 by U.S. News & World Report.
Researchers from Boston University's Slone Epidemiology Center (SEC), in collaboration with Harvard School of Public Health, have found numerous prescription and over-the-counter drugs and supplements use certain chemicals called phthalates as inactive ingredients in their products.
› Verified 9 days ago
Sarah Miller, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 222 N 7th St, Bismarck, ND 58501 Phone: 701-323-5422 Fax: 701-323-8645 | |
Danette Pengilly, GNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 310 N 10th St, Bismarck, ND 58501 Phone: 701-530-7500 Fax: 701-530-7484 | |
Jana Rakowski, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1040 Tacoma Ave, Bismarck, ND 58504 Phone: 701-323-7452 Fax: 701-323-6982 | |
Mrs. Christina R Gisvold, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 300 N 7th St, Bismarck, ND 58501 Phone: 701-323-6000 | |
Lee Ann June Short, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 300 N 7th St, Bismarck, ND 58501 Phone: 701-204-1709 | |
Rebecca L Ritter, NP-C Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1000 E Rosser Ave, Bismarck, ND 58501 Phone: 701-530-6000 Fax: 701-530-6430 | |
Cheryle K Bitz, MSN, ARNP, GNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 900 E Broadway Ave, Bismarck, ND 58501 Phone: 701-530-7300 Fax: 701-530-7319 |